Skip to main content
OpenTrials
Completed

NCT Number: NCT00619073

PACT (Platelet Activity After Clopidogrel Termination)

Clopidogrel is a medication that is used to decrease the ability of platelets to form blood clots.

The theory has been proposed that, in patients with coronary artery disease or stroke, increased platelet function after discontinuation of clopidogrel therapy is associated with an increased clotting risk. However, this theory has never been rigorously tested.

The goal of this research is to determine whether discontinuation of clopidogrel results in increased platelet function.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Blood Platelets Clopidogrel

Age range

21 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Massachusetts Medical School

Worcester, Massachusetts, 01655-0002, United States

About this study

In this study, we will address the question: does discontinuation of clopidogrel result in platelet hyperreactivity? We will perform a double-blind, placebo-controlled, crossover study in normal subjects, in whom platelet reactivity will be measured before clopidogrel or placebo, during clopidogrel or placebo, and at various time points after discontinuation of clopidogrel or placebo. The dose of clopidogrel will be the standard, FDA-approved dose: 75 mg daily. All subjects will be treated with aspirin 81 mg daily throughout the 57 days of study assessment in both the clopidogrel arm and the placebo arm, because the clinically relevant question is: in patients who remain on aspirin, does discontinuation of clopidogrel result in platelet hyperreactivity?

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must be a normal healthy subject
  • Must be between 21-70 years old
  • Must be able to take aspirin and clopidogrel.
  • Must be able to have blood drawn 16 times over approximately 3 months.

Exclusion criteria

  • Subject who is currently taking aspirin or another anti-platelet drug such as clopidogrel. Subject must be free of these medications for 10 days before enrolling in this study.
  • Subject who is currently taking a non-steroidal anti-inflammatory drug such as ibuprofen or naproxen. Subject must be free of these medications for 3 days before enrolling in this study.
  • Subject who is currently taking medications for depression or medications that lower blood pressure or lower blood sugar.
  • Subject who are pregnant or may become pregnant during the study or who is breast feeding.
  • Subject with a known allergy to aspirin or clopidogrel.
  • Cigarette smoking or use of other nicotine product.
  • Subject with a history of any of the following: coronary artery disease; stroke; bleeding disorder; ongoing bleeding; previous life-threatening hemorrhage; stomach ulcers; gastrointestinal bleeding within the past 1 month; major surgery within the past 1 month; minor surgery within the past 2 weeks; or platelet transfusion within the past 7 days.
  • Subject with a blood count, measured on the pre-study drug blood sample, that is not in the normal range.
  • Subject who is enrolled in another clinical trial of an investigational drug.

Treatment and study plan

clopidogrel + aspirin

Drug

Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.

Other names: Plavix, aspirin

Placebo

Drug

Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.

Other names: aspirin

Aspirin

Drug

Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.

Primary outcomes

  1. Change From Baseline in Platelet Surface Activated GPIIb-IIIa Complex at 45 Days After Intervention.

    Time frame: Baseline and 45 days after intervention

    Value at 45 days after intervention minus value at baseline in platelet surface activated GPIIb-IIIa complex using flow cytometry.The types and concentrations of agonists used in the flow cytometry assays reported here were: ADP 0.5, 1, and 20 µmol/L; thrombin receptor activating peptide (TRAP) 1 and 20 µmol/L; and a combination of collagen 5 µg/mL and epinephrine 5 µmol/L. Mean Florescence Intensity (MFI) is used as unit of measure. MFI indicates relative degree of shift in fluorescence intensity of a population of platelets in arbitrary units.

Sponsors and collaborators

Lead sponsor

University of Massachusetts, Worcester

Other

Collaborators

  • Bristol-Myers Squibb
  • Sanofi

Registry information

Acronym: PACT

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Feb 20, 2008
Registry last updated
May 31, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.